Last reviewed 2026-04-23 · How we verify

HRS-9231

HRS-9231 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and angiogenesis.

HRS-9231 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and angiogenesis. Used for Solid tumors (specific indications in phase 3 development).

At a glance

Mechanism of action

HRS-9231 inhibits receptor tyrosine kinases and intracellular signaling pathways critical for tumor growth and neovascularization. By blocking these kinases, the drug suppresses cancer cell proliferation and reduces tumor blood supply. It is being developed as an oral small-molecule therapeutic for solid tumors.

Approved indications

• Solid tumors (specific indications in phase 3 development)

Common side effects

• Diarrhea
• Fatigue
• Nausea
• Hypertension

Key clinical trials

• A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions (PHASE3)
• A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions (PHASE3)
• Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects (PHASE1)
• Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function (PHASE1)
• A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions (PHASE2)
• Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.